Patients with PD-/LAG3 expressing melanoma whose disease had become refractory to anti PD-1/PD-L1 treatment responded better to combination of Nivolumab with Relatimab, a LAG3 targeting monoclonal antibody. The gene discussed is LAG3; the disease is melanoma.